Candel Therapeutics shares positive survival data for investigational immunotherapy in NSCLC

By Proactive Investors / March 27, 2025 / www.youtube.com / Article Link


Candel Therapeutics CEO Dr. Paul Peter Tak joined Steve Darling from Proactive to announce final survival data from a Phase 2a ...

Share to Youtube Share to Facebook Facebook Share to Linkedin Share to Twitter Twitter Share to Tiktok